149 related articles for article (PubMed ID: 18347174)
1. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract][Full Text] [Related]
2. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Chen Z; Fan Z; McNeal JE; Nolley R; Caldwell MC; Mahadevappa M; Zhang Z; Warrington JA; Stamey TA
J Urol; 2003 Apr; 169(4):1316-9. PubMed ID: 12629351
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
4. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
5. Expression signatures that correlated with Gleason score and relapse in prostate cancer.
Bibikova M; Chudin E; Arsanjani A; Zhou L; Garcia EW; Modder J; Kostelec M; Barker D; Downs T; Fan JB; Wang-Rodriguez J
Genomics; 2007 Jun; 89(6):666-72. PubMed ID: 17459658
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
7. Cancer gene profiling in prostate cancer.
Foye A; Febbo PG
Methods Mol Biol; 2010; 576():293-326. PubMed ID: 19882268
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.
Nanni S; Priolo C; Grasselli A; D'Eletto M; Merola R; Moretti F; Gallucci M; De Carli P; Sentinelli S; Cianciulli AM; Mottolese M; Carlini P; Arcelli D; Helmer-Citterich M; Gaetano C; Loda M; Pontecorvi A; Bacchetti S; Sacchi A; Farsetti A
Mol Cancer Res; 2006 Feb; 4(2):79-92. PubMed ID: 16513839
[TBL] [Abstract][Full Text] [Related]
9. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
[TBL] [Abstract][Full Text] [Related]
10. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
11. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
Tsunoda T; Furusato B; Takashima Y; Ravulapalli S; Dobi A; Srivastava S; McLeod DG; Sesterhenn IA; Ornstein DK; Shirasawa S
Prostate; 2009 Sep; 69(13):1398-403. PubMed ID: 19479898
[TBL] [Abstract][Full Text] [Related]
12. Discovery of prostate cancer biomarkers by microarray gene expression profiling.
Sørensen KD; Ørntoft TF
Expert Rev Mol Diagn; 2010 Jan; 10(1):49-64. PubMed ID: 20014922
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
Arencibia JM; Martín S; Pérez-Rodríguez FJ; Bonnin A
Int J Oncol; 2009 Feb; 34(2):457-63. PubMed ID: 19148481
[TBL] [Abstract][Full Text] [Related]
14. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.
Schlomm T; Chun FKh; Erbersdobler A
Methods Mol Biol; 2010; 664():177-89. PubMed ID: 20690063
[TBL] [Abstract][Full Text] [Related]
15. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.
Lin DW; Coleman IM; Hawley S; Huang CY; Dumpit R; Gifford D; Kezele P; Hung H; Knudsen BS; Kristal AR; Nelson PS
J Clin Oncol; 2006 Aug; 24(23):3763-70. PubMed ID: 16822846
[TBL] [Abstract][Full Text] [Related]
16. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
17. Genes differentially expressed in prostate cancer.
Eder IE; Bektic J; Haag P; Bartsch G; Klocker H
BJU Int; 2004 May; 93(8):1151-5. PubMed ID: 15142130
[TBL] [Abstract][Full Text] [Related]
18. Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study.
Bettuzzi S; Scaltriti M; Caporali A; Brausi M; D'Arca D; Astancolle S; Davalli P; Corti A
Cancer Res; 2003 Jul; 63(13):3469-72. PubMed ID: 12839927
[TBL] [Abstract][Full Text] [Related]
19. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer.
Lexander H; Palmberg C; Hellman U; Auer G; Hellström M; Franzén B; Jörnvall H; Egevad L
Proteomics; 2006 Aug; 6(15):4370-80. PubMed ID: 16888723
[TBL] [Abstract][Full Text] [Related]
20. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.
Yu YP; Landsittel D; Jing L; Nelson J; Ren B; Liu L; McDonald C; Thomas R; Dhir R; Finkelstein S; Michalopoulos G; Becich M; Luo JH
J Clin Oncol; 2004 Jul; 22(14):2790-9. PubMed ID: 15254046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
